Update on Novel Therapies in Acute Lymphoblastic Leukemia

Program Overview

Acute lymphoblastic leukemia (ALL) is a serious hematologic malignancy associated with substantial morbidity and mortality. While 89% to 90% of adults with ALL achieve a complete response, half of them will relapse. The use of pediatric-inspired regimens, minimal residual disease (MRD)-directed therapy, biologics, and CAR T-cell therapy may yield important benefits in adolescent/young adult patients and adults with ALL. Patient education regarding potential adverse events, expectations, and treatment adherence is critical for optimizing outcomes. In this case-based activity, participants will evaluate the diagnosis and risk stratification of two patients with ALL, select induction regimens—including novel agents—and apply strategies to mitigate toxicities.

Learning Objectives

Upon completion of this activity, participants should be better able to:

Describe clinical factors, subtypes, and cytogenetic factors that impact diagnosis and classification of ALL
Identify evidence for novel and emerging agents for ALL
Apply strategies to mitigate toxicities associated with novel therapies